13 results about "Multiple organ dysfunction syndrome" patented technology

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the disclosure relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

The PN composition for treating multiple organ dysfunction syndrome (MODS) comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and / or liposomes organized as lipid bilayers and / or other particle configurations, which are capable of taking up nitric oxide and releasing it with enhanced rapidity, shifting the nitric oxide balance from one that worsens organ damage and reduces survival to one that reverses and / or inhibits organ damage and increases survival.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein moiety A, R1, and R2 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia- reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism- related disease and genetic disorder of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the disclosure relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, receiving a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, (I) wherein cycle A, R1, R2, and R3 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism-related disease and genetic disorders of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.

To provide an in vitro method for assessing the risk of developing sepsis, systemic inflammatory response syndrome (SIRS), septic shock, or multiple organ dysfunction syndrome (MODS) in a subject. Also provided are pharmaceutical compositions for the treatment of sepsis, SIRS, septic shock or MODS in a subject.SOLUTION: Determining or having determined the presence or absence of i) a PCSK9 variant nucleic acid sequence encoding a Pro-protein convertase subtilisin / kexin type 9 (Arg46Leu) PCSK9; and ii) a low-density-lipoprotein receptor (LDLR) variant nucleic acid sequence comprising a single nucleotide polymorphism rs6511720 in a biological sample obtained from the subject, wherein the subject is a PCSK9 reference and being a LDLR reference indicates that the subject has an increased risk of developing SIRS / MODS.SELECTED DRAWING: None

Methods of preventing and / or treating ischemia, organ dysfunction and / or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction / failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

The invention discloses application of CLK1 in sepsis, it is determined that an ALKBH5 / m6A / CLK1 signal axis and an ALKBH5 / m6A / CLK1 signal channel targeting macrophages can effectively enhance sepsis immune response, promote macrophage infiltration, reduce bacterial load in abdominal cavity lavage fluid and main organs of lung, spleen, liver and kidney and improve sepsis survival rate, and meanwhile, the ALKBH5 / m6A / CLK1 signal axis and the ALKBH5 / m6A / CLK1 signal channel targeting the macrophages can effectively enhance sepsis immune response, promote macrophage infiltration and improve sepsis survival rate. And pathological changes in main organs such as lung, spleen, liver and kidney are improved. The invention provides a new treatment way for integrating a post-transcriptional modification targeting strategy and an immunotherapy to treat sepsis, and has important significance for treating and preventing sepsis and improving multi-organ dysfunction syndrome caused by sepsis.

The application provides a multiple organ dysfunction syndrome monitoring system and application thereof. The multiple organ dysfunction syndrome monitoring system is used for monitoring tissue-specific methylation genes related to damage of six kinds of tissue organs, i.e. heart, liver, lung, kidney, intestine and pancreas. The bisDNA sequence of each gene and the bisDNA sequence of the internal reference ACTB gene are simultaneously detected, and finally, a multiple combined qMS-PCR method of 6 genes is screened out, which is used for high-sensitivity and high-specificity detection of the methylation sites.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, R3, and R4 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, and iron metabolism-related disease. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament.

The invention discloses a Lateococcus-bifidobacterium adolescentis microbial composition and application thereof in preparation of a medicine for preventing and treating liver injury related to multi-organ dysfunction syndrome. Belongs to the field of biomedicine. According to the invention, the microbial combination is composed of the Brawococcus and the Bifidobacterium adolescentis and is applied to prevention and treatment of liver injury related to the multi-organ dysfunction syndrome. According to the composition, effective intervention on the'intestine-liver axis' vicious circle is realized through a precise synergistic mechanism, so that the technical problem that an existing broad-spectrum microecological preparation lacks targeting and synergy under extreme pathological conditions is solved. The specific combination of the Brawococcus and the Bifidobacterium adolescentis, provided by the invention, can remarkably up-regulate the intestinal acetic acid level and effectively relieve liver inflammation and injury, the protection effect of the specific combination is superior to that of a single strain, and a new strategy is provided for developing a targeted microecological preparation.

This invention provides methods for treating or preventing multiple organ dysfunction syndrome. [Solution] A method for treating multiple organ dysfunction syndrome (MODS) in a subject, comprising administering to a subject in need of treatment an effective amount of a phospholipid nanoparticle (PN) composition comprising 0-35% (w / v) of a lipophilic or hydrophobic component, 0.1-60% (w / v) of an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, wherein the PN composition comprises liposomes and / or micelles having a diameter of 1-800 nm.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, and R3 have the same meaning as that defined in the claims and the description, wherein said compound is used as a medicament for oral administration. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism-related disease and genetic disorders of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as medicament for oral administration in methods of prevention and / or treatment of such diseases.